Elisabeth M. C. Schrijvers and colleagues examined the associations between plasma levels of clusterin and the prevalence, severity, and risk of Alzheimer’s disease. The study included analysis of data on plasma levels of clusterin measured at baseline (1997-1999) in 60 individuals with prevalent Alzheimer’s disease, a random sub-group of 926 participants, and an additional 156 participants diagnosed with Alzheimer’s disease during follow-up (average, 7.2 years) until January 2007.
The researchers found that the likelihood of prevalent Alzheimer’s disease increased with increasing plasma levels of clusterin, with the odds increased by 63 percent for every standard deviation increase in clusterin levels, after adjusting for age, sex, education level, apolipoprotein E status, diabetes, smoking, coronary heart disease, and hypertension. Among patients with Alzheimer’s disease, higher clusterin levels were associated with more severe disease.
There was no statistically significant association of plasma clusterin levels with new Alzheimer’s disease during total follow-up or with new Alzheimer’s disease within or after 3 years of baseline. Results for all-cause dementia and vascular dementia were similar.
“In conclusion, our data from the general population show that increased plasma clusterin levels are associated with prevalent Alzheimer’s disease and are higher in more severe cases of Alzheimer’s disease. However, increased levels of clusterin do not precede development of Alzheimer’s disease and therefore are not a potential early marker of subclinical disease,” the authors write.
1. Elisabeth M. C. Schrijvers, et al. Plasma Clusterin and the Risk of Alzheimer Disease. JAMA. 2011;305(13):1322-1326. DOI: 10.1001/jama.2011.381